395 results Stibbe advises Tornier Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion. Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business. Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets. Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here. Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products. Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding. Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency. Stibbe advises on the IPO of Tornier Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix. Aanbevelingen van het Pbl voor de circulaire economie: meer bestuursrechtelijke verplichtingen voor bedrijven? Begin dit jaar publiceerde het Planbureau voor de leefomgeving (Pbl) zijn eerste Integrale Circulaire Economie Rapportage. Die rapportage bespreekt de huidige status van de circulaire economie in Nederland en geeft adviezen om de transitie te versnellen. Environmental and financial worlds meet in the “E” of ESG Developments in the environmental and financial worlds may appear to be at first sight completely separate from each other. In this blog post, we will explain why this no longer applies in 2021. The European Climate Law explained Co-legislators on the European Climate Law reached a provisional agreement on April 21, 2021. This Climate Law is one of the key elements of the European Green Deal, published by the European Commission in December 2019. E-book: 'Sustainable Finance in Europe' Stibbe lawyers Marieke Driessen, Loes van Dijk and Ingrid van der Klooster contributed to the book 'Sustainable Finance in Europe' which was recently published. Richtlijn beloningstransparantie: waterval aan gelijkebeloningsclaims aanstaande? In mei 2023 is de Richtlijn beloningstransparantie (de Richtlijn) in het EU-Publicatieblad verschenen. Deze Richtlijn beoogt de transparantie op het gebied van gelijke beloning tussen mannen en vrouwen te vergroten. Pagination Previous page Page 13 Current page 14 Page 15 Page 16 Next page
Stibbe advises Tornier Stibbe advises Tornier N.V. on its merger with Wright Medical Group, Inc. in an all stock transaction with a combined equity value of approximately $3.3 billion.
Stibbe advises Mylan Stibbe advises Mylan Inc., the pharmaceuticals company listed on the NASDAQ with a market cap of approximately $19 billion, on the inversion acquisition of Abbott’s non-U.S. developed markets specialty and branded generics business.
Stibbe advises Aedifica Stibbe advised Aedifica recently on two transactions in order to further expand her Dutch portfolio of care assets.
Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of a care residence that will be constructed in Leersum. Aedifica acquired the full property of the site from Woudenburcht B.V., a local real estate developer. See for the press release here.
Stibbe represents Simed in dispute with Slotervaart hospital Stibbe represented Simed International in a dispute with the privately-owned Slotervaart hospital in Amsterdam. The Slotervaart hospital claimed that Simed International had sent incorrect invoices to the Slotervaart hospital, which would therefore have b
Stibbe advises client in the pharmaceutical sector Stibbe assisted a client in the pharmaceutical sector with conducting an in-depth legal assessment regarding the scope and modalities of the safety features to be added to (the packaging of) medicinal products.
Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.
Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.
Stibbe advises Cellerix Stibbe assisted Cellerix with its merger with Euronext-Brussels-listed Tigenix.
Aanbevelingen van het Pbl voor de circulaire economie: meer bestuursrechtelijke verplichtingen voor bedrijven? Begin dit jaar publiceerde het Planbureau voor de leefomgeving (Pbl) zijn eerste Integrale Circulaire Economie Rapportage. Die rapportage bespreekt de huidige status van de circulaire economie in Nederland en geeft adviezen om de transitie te versnellen.
Environmental and financial worlds meet in the “E” of ESG Developments in the environmental and financial worlds may appear to be at first sight completely separate from each other. In this blog post, we will explain why this no longer applies in 2021.
The European Climate Law explained Co-legislators on the European Climate Law reached a provisional agreement on April 21, 2021. This Climate Law is one of the key elements of the European Green Deal, published by the European Commission in December 2019.
E-book: 'Sustainable Finance in Europe' Stibbe lawyers Marieke Driessen, Loes van Dijk and Ingrid van der Klooster contributed to the book 'Sustainable Finance in Europe' which was recently published.
Richtlijn beloningstransparantie: waterval aan gelijkebeloningsclaims aanstaande? In mei 2023 is de Richtlijn beloningstransparantie (de Richtlijn) in het EU-Publicatieblad verschenen. Deze Richtlijn beoogt de transparantie op het gebied van gelijke beloning tussen mannen en vrouwen te vergroten.